These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36826148)

  • 1. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.
    Parosanu AI; Pirlog CF; Slavu CO; Stanciu IM; Cotan HT; Vrabie RC; Popa AM; Olaru M; Iaciu C; Bratu LI; Baicoianu IF; Moldoveanu O; Baston C; Nițipir C
    Curr Oncol; 2023 Feb; 30(2):2457-2464. PubMed ID: 36826148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
    Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
    Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
    Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
    Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma.
    Sato MT; Ida A; Kanda Y; Takano K; Ohbayashi M; Kohyama N; Morita J; Fuji K; Sasaki H; Ogawa Y; Kogo M
    BMC Cancer; 2022 Nov; 22(1):1214. PubMed ID: 36434552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.
    Tjokrowidjaja A; Goldstein D; Hudson HM; Lord SJ; Gebski V; Clarke S; de Souza P; Motzer RJ; Lee CK
    Acta Oncol; 2020 Jan; 59(1):20-27. PubMed ID: 31462137
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
    Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
    J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
    Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
    Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
    Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
    Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
    Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
    Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
    Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
    J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
    Nader Marta G; Isaacsson Velho P; Bonadio RRC; Nardo M; Faraj SF; de Azevedo Souza MCL; Muniz DQB; Bastos DA; Dzik C
    Pathol Oncol Res; 2020 Oct; 26(4):2489-2497. PubMed ID: 32583330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
    Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
    Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.
    Na N; Yao J; Cheng C; Huang Z; Hong L; Li H; Qiu J
    Oncotarget; 2016 Jul; 7(28):44039-44046. PubMed ID: 27270655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
    Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
    Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
    Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
    Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.